Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large m...

Source: BMC Cancer - May 30, 2019 Category: Cancer & Oncology Authors: Mark T. J. van Bussel, Jos H. Beijnen and Dieta Brandsma Tags: Research article Source Type: research